TSO3 announces the results of the vote for the election of the members of the Board of Directors

Ticker:  TSX - TOS  
Shares Outstanding: 72,888,182

QUEBEC CITY, May 9, 2013 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Corporation"), an innovator in low temperature sterilization technology for medical devices in healthcare settings, announced that the nominees listed in the management proxy circular dated April 12, 2013, were elected as directors of TSO3 Inc.

Election of Directors

The shareholders were asked to provide their decision via a vote by proxy as part of TSO3 Annual General Meeting of Shareholders, held on May 8 2013 in Montreal. The detailed results of the vote are set out below.

Name of Nominee Votes for % for Votes
% Against Votes
% Withheld
Germain Carrière 33,987,698 99,57% 0 0% 148,400 0,43%
Pierre Désy 32,288,098 94,59% 0 0% 1,848,000 5,41%
James R. Husman 34,077,998 99,83% 0 0% 58,100 0,17%
Jean Lamarre 34,075,203 99,82% 0 0% 59,995 0,18%
W. Barry McDonald 34,080,998 99,84% 0 0% 55,100 0,16%
Claude Michaud 34,085,298 99,85% 0 0% 50,800 0,15%
Simon Robitaille 34,073,698 99,82% 0 0% 62,400 0,18%
Richard M. Rumble 34,083,498 99,85% 0 0% 52,600 0,15%

Final voting results on all matters voted at the Annual Meeting of Shareholders held on May 8, 2013, will be filed on SEDAR (www.sedar.com) under the name TSO3.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals. For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.


For further information:

Caroline Côté
Director - Investor and Business Relations
418 651-0003, Ext. 237


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.